Cytosorbents Corp (NASDAQ:CTSO) – B. Riley decreased their Q3 2018 EPS estimates for shares of Cytosorbents in a research note issued to investors on Wednesday, October 31st. B. Riley analyst A. D’silva now forecasts that the medical research company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.14). B. Riley also issued estimates for Cytosorbents’ Q4 2018 earnings at ($0.13) EPS, FY2019 earnings at ($0.30) EPS and FY2020 earnings at $0.03 EPS.
Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, August 2nd. The medical research company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). Cytosorbents had a negative return on equity of 100.51% and a negative net margin of 74.60%. The business had revenue of $5.76 million for the quarter, compared to analysts’ expectations of $5.08 million.
CTSO has been the topic of several other reports. BidaskClub upgraded Cytosorbents from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Maxim Group restated a “buy” rating and set a $18.00 target price on shares of Cytosorbents in a research note on Tuesday, September 4th. Finally, Cowen restated a “buy” rating and set a $15.00 target price on shares of Cytosorbents in a research note on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $14.56.
Shares of CTSO stock opened at $9.89 on Friday. Cytosorbents has a 1-year low of $5.80 and a 1-year high of $14.95. The company has a current ratio of 8.82, a quick ratio of 8.60 and a debt-to-equity ratio of 0.46. The firm has a market cap of $301.38 million, a P/E ratio of -30.91 and a beta of 0.19.
Institutional investors and hedge funds have recently modified their holdings of the business. Pegasus Partners Ltd. acquired a new stake in Cytosorbents during the 2nd quarter worth about $114,000. P.A.W. Capital Corp acquired a new stake in Cytosorbents during the 3rd quarter worth about $129,000. Metropolitan Life Insurance Co. NY acquired a new stake in Cytosorbents during the 2nd quarter worth about $119,000. Mycio Wealth Partners LLC acquired a new position in shares of Cytosorbents in the 3rd quarter valued at about $166,000. Finally, PEAK6 Investments L.P. acquired a new position in shares of Cytosorbents in the 2nd quarter valued at about $168,000. 24.78% of the stock is owned by institutional investors.
In other Cytosorbents news, CEO Phillip P. Chan sold 5,787 shares of Cytosorbents stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $14.85, for a total transaction of $85,936.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Vincent Capponi sold 9,565 shares of Cytosorbents stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $13.00, for a total value of $124,345.00. Following the sale, the chief operating officer now directly owns 342,333 shares of the company’s stock, valued at approximately $4,450,329. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,501 shares of company stock worth $927,310. 6.90% of the stock is owned by company insiders.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Further Reading: Terms to Better Understand Call Options
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.